Pharming Group (NASDAQ:PHAR - Get Free Report) shares saw strong trading volume on Wednesday . 7,607 shares changed hands during mid-day trading, an increase of 42% from the previous session's volume of 5,358 shares.The stock last traded at $8.86 and had previously closed at $9.00.
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on PHAR. Jefferies Financial Group assumed coverage on Pharming Group in a report on Monday, December 9th. They set a "buy" rating and a $14.00 price objective for the company. Oppenheimer cut their price objective on Pharming Group from $31.00 to $30.00 and set an "outperform" rating on the stock in a report on Monday, October 28th. Finally, HC Wainwright reiterated a "buy" rating and set a $37.00 target price on shares of Pharming Group in a report on Tuesday, December 17th.
Read Our Latest Analysis on Pharming Group
Pharming Group Trading Down 0.1 %
The firm has a fifty day moving average of $9.04 and a 200-day moving average of $8.43. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The stock has a market capitalization of $610.13 million, a price-to-earnings ratio of -34.60 and a beta of -0.08.
Hedge Funds Weigh In On Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its position in Pharming Group (NASDAQ:PHAR - Free Report) by 75.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 41,110 shares of the company's stock after acquiring an additional 17,675 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.06% of Pharming Group worth $339,000 as of its most recent filing with the Securities and Exchange Commission. 0.03% of the stock is owned by institutional investors and hedge funds.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
